Genetic Technologies Ltd - רווח נקי למניה בארבעת הרבעונים האחרונים GENE
Genetic Technologies serves as a global diagnostic partner, implementing genetic cancer risk screenings in clinics. The annual EPS (TTM) growth rate is currently trading in a sideways range, where the -53.10 metric determines the status of the parameter. Synergy with distributors via AI tests is advancing personalized medicine, while increasing sales of prostate and breast cancer diagnostics are reducing the impact of fixed costs.
GENE (Genetic Technologies Ltd): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The efficiency of integrating GeneType tests into medical practice is directly reflected in profit dynamics. This annual growth in basic net income per share (ttm) measures the percentage change in EPS over the last twelve months relative to the previous year. Analysis of this chart reveals the pace of business scaling and the stability of cash flows. Sharp fluctuations in the indicator signal revenue volatility from preventive genomics. Stable growth confirms the fundamental value of Genetic Technologies (GENE) assets.
